C4 Therapeutics, Inc. (CCCC) has been beaten down lately with too much selling pressure. While the stock has lost 21.9% over the past four weeks, there is light at the end of the tunnel as it is now ...

The price trend for C4 Therapeutics, Inc. (CCCC) has been bearish lately and the stock has lost 7% over the past week. However, the formation of a hammer chart pattern in its last trading session ...

The average one-year price target for C4 Therapeutics (NasdaqGS:CCCC) has been revised to $10.05 / share. This is a decrease of 13.75% from the prior estimate of $11.66 dated January 11, 2026. The ...

As of September 13, 2025, the average one-year price target for C4 Therapeutics is $14.79/share. The forecasts range from a low of $3.03 to a high of $52.50. The average price target represents an ...

Chinese state-owned engineering giant China Communications Construction Company (CCCC) will counter growing uncertainty in the growth of its overseas projects, some of which has been caused by US ...

Investing.com -- Moody’s Ratings has confirmed the Baa1 issuer rating and ba1 Baseline Credit Assessment (BCA) for China Communications Construction Co., Ltd. (CCCC). The ratings for the subordinated ...

A downtrend has been apparent in C4 Therapeutics, Inc. (CCCC) lately with too much selling pressure. The stock has declined 23.1% over the past four weeks. However, given the fact that it is now in ...